Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Oronsky

Showing results (21-30 of 115) with videos related to

Pageof 12
Sort By:
Anti-Cancer Agents in Medicinal Chemistry|June 5, 2014
Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessmentBryan Oronsky, Neil Oronsky, Susan Knox, et al.
Biochemical and Biophysical Research Communications|April 17, 2014
Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapyShoucheng Ning, Mark Bednarski, Bryan Oronsky, et al.
Seminars in Oncology|June 11, 2020
Just eat it: A review of CD47 and SIRP-α antagonismBryan Oronsky, Corey Carter, Tony Reid, et al.
Molecular Cancer Therapeutics|February 1, 2024
Predicting the Abscopal Phenomenon-Letter to the EditorAnthony P Conley, Bryan Oronsky, Scott Caroen, et al.
Journal for Immunotherapy of Cancer|October 26, 2024
TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistanceTony R Reid, Bryan Oronsky, Jeannie Williams, et al.
Translational Oncology|April 16, 2014
The implications of hyponitroxia in cancerBryan Oronsky, Gary R Fanger, Neil Oronsky, et al.
Seminars in Oncology|July 29, 2020
Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19Bryan Oronsky, Susan Knox, Pedro Cabrales, et al.
American Journal of Cancer Research|November 12, 2021
Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-betaChristopher Larson, Bryan Oronsky, Nacer E Abrouk, et al.
Frontiers in Oncology|June 21, 2023
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastomaHoward Fine, Tony Reid, Scott Caroen, et al.
Asian Journal of Transfusion Science|February 28, 2015
Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shockChad Brouse, Daniel Ortiz, Yan Su, et al.
Pageof 12

Showing results (21-30 of 115) with videos related to

Sort By:
Pageof 12
Anti-Cancer Agents in Medicinal Chemistry|June 5, 2014
Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessmentBryan Oronsky, Neil Oronsky, Susan Knox, et al.
Biochemical and Biophysical Research Communications|April 17, 2014
Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapyShoucheng Ning, Mark Bednarski, Bryan Oronsky, et al.
Seminars in Oncology|June 11, 2020
Just eat it: A review of CD47 and SIRP-α antagonismBryan Oronsky, Corey Carter, Tony Reid, et al.
Molecular Cancer Therapeutics|February 1, 2024
Predicting the Abscopal Phenomenon-Letter to the EditorAnthony P Conley, Bryan Oronsky, Scott Caroen, et al.
Journal for Immunotherapy of Cancer|October 26, 2024
TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistanceTony R Reid, Bryan Oronsky, Jeannie Williams, et al.
Translational Oncology|April 16, 2014
The implications of hyponitroxia in cancerBryan Oronsky, Gary R Fanger, Neil Oronsky, et al.
Seminars in Oncology|July 29, 2020
Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19Bryan Oronsky, Susan Knox, Pedro Cabrales, et al.
American Journal of Cancer Research|November 12, 2021
Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-betaChristopher Larson, Bryan Oronsky, Nacer E Abrouk, et al.
Frontiers in Oncology|June 21, 2023
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastomaHoward Fine, Tony Reid, Scott Caroen, et al.
Asian Journal of Transfusion Science|February 28, 2015
Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shockChad Brouse, Daniel Ortiz, Yan Su, et al.
Pageof 12